MEDIUM-PRESSURE HYPERBARIC OXYGEN THERAPY FOR LIVEDOID VASCULOPATHY

ALEJANDRO HERRERA-SÁNCHEZ1, MARÍA JOSÉ MADRIAGAL-ALVARADO2, GABRIELA MONCAYO3, FABRIZIO VERDINI3

1FisioSport Costa Rica, Biobarica Costa Rica, 2Caja Costarricense del Seguro Social, Costa Rica, 3Asociación Argentina de Medicina Hiperbárica e Investigación (AAMHEI), Buenos Aires, Argentina

Abstract  Livedoid vasculopathy (LV) is a cutaneous manifestation of several diseases that lead to non-inflammatory thrombosis of dermal vessels. We report the case of a 26-year-old female with a 4 years and 8 months-old history of diagnosis of LV and a non-healing ulcer of more than a year of evolution. Because of refractory response to standard care, low-pressure hyperbaric oxygen (LPHBOT) was added to the therapeutic scheme (azathiopine 2.5 mg/kg, folic acid and acetylsalicylic acid). After 12 sessions of LHBOT (60 min, 1.45 ATA ≈ 100% O2), ulcers achieved complete healing with significant pain relief and no recurrence was present over 6 months. More studies are necessary to determine the effectiveness of HBOT for LV treatment.

Key words: hyperbaric oxygen therapy, livedoid vasculopathy, ulcers

CASE REPORT

Received: 1-VI-2021  Accepted: 4-III-2022

Postal address: Fabrizio Verdini, Ceretti 3320, 1429 Buenos Aires, Argentina  
e-mail: investigacion@aamhei.org
We report a case of this pathology treated with a low-pressure hyperbaric oxygen treatment (lower than 2 ATA).

This case report suggests that low pressure hyperbaric oxygenation therapy is a quick and effective alternative for the treatment of livedoid vasculopathy that does not respond to conventional antiplatelet, immunomodulatory therapy or oral corticosteroids.

Clinical case

A 26-year-old female, non-smoker, presented with a 4 year and 8 months-old history of recurrent multiple non-healing ulcers involving feet and ankles. The wounds were associated with severe pain and inflammation. Examination also revealed evidence of previous ulceration in the form of multiple hyper-pigmented scars on both feet and ankles.

The patient had been undergoing treatment with 2.5 mg / kg azathioprine, 15 mg/day prednisone for 22 days, folic acid and acetylsalicylic acid for two years, which had good results during the first year, but presented poor evolution in the second. A biopsy was performed and the results obtained confirmed the diagnosis of livedoid vasculopathy, for which the treatment with azathioprine was suspended. Histological findings revealed the upper dermis with capillaries with fibrin deposition on their walls and fibrin thrombi with perivascular lymphocytic inflammation and erythrocyte extravasation.

Patient did not give any history of any medical illness. The blood platelets value was within normal parameters. Systemic vasculitis, antiphospholipid syndrome and systemic lupus erythematosus were ruled out. There were no comorbidities or associated pathology.

She reported multiple recurrences in the last year, with higher levels of pain and inflammation, and also the presence of a painful refractory ulcer of a one and a half year-old evolution, with dermatitis and small painful macules, papules with purpuric erythematous plaques with small superficial ulcers on both feet. She presented a history of recurrent dermatitis with small, painful ulcers and 4 very strong episodes lasting between 2 and 6 months before.

Hyperbaric oxygen therapy was indicated as adjuvant therapy with a session of 60 min ≈ 100%O2 at 1.45 ATA (Revitalair 430 by Biobarica chamber). The two first weeks the treatment was three times a week and the following weeks was twice a week.

Complete healing and significant pain reduction was observed after 12 sessions (Fig. 1). Follow-up was indicated to evaluate relapse-free time. The patient referred relief with a...
few sessions. She had complete healing of all ulcers, leaving white polygonal scars with peripheral hyper-pigmented macules. New lesions ceased to develop and she had not recurrence for the following sixteen months.

**Discussion**

LV is the cutaneous manifestation of several diseases that lead to non-inflammatory thrombosis of dermal vessels. Reduced fibrinolytic activity in the blood of these patients, with reduced release of tissue plasminogen activator from vessel walls, leads to demonstrated increased aggregation activity. A variety of treatments with varying degrees of success have been used to treat LV. The efficacy of anticoagulants supports the main proposed pathogenic mechanism for LV of an occlusive vasculopathy. HBOT was described as treatment for LV in few cases, generally in combination with other drugs to be able to achieve remission. It has been shown that HBOT is able to increase the release of various fibrinolytic molecules from endothelial cells. In vitro, in an ischaemia-reperfusion model using cultured endothelial cells, HBO stimulated the secretion of fibrinolytic factors including urokinase, plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1).

Although clinical use of HBOT was defined at more than 1.4 ATA, some authors suggest higher pressure hyperbaric for wound treatment. Actually, there is a rapid emergence of more accessible, safer and portable hyperbaric chamber working at lower pressures. Low pressure hyperbaric oxygen therapy is effective and proposed to neurological diseases but right now it is used in some refractory wounds. Physiological benefits like angiogenesis, collagen synthesis and endothelial anti-inflammation are achieved at a pressure as safe as 1.45 ATA. HBOT at 1.45 ATA generates a physical dissolution of oxygen in plasma and tissue fluids 10 times higher than that achieved by breathing room air at norm baric pressure. Thus, HBOT uses hyperbaric chambers that work at 1.45 ATA are effective in tissue oxygenation. It creates a high oxygen gradient across the wound site and counteracts the damaging effect of tissue ischaemia.

Authors had first used higher pressure HBOT for the management of LV with rapid healing of ulcers and significant reduction in pain. As far as we are aware, this is the first report of low-pressure HBOT for LV treatment. We report pain relief with a few sessions and complete healing after 12 sessions of HBOT at 1.45 ATA. More studies and clinical cases series are necessary to demonstrate if low-pressure HBOT is effective for LV treatment and quality life improvement in these patients.

**Conflict of interest:** Fabrizio Verdini is a professional in Argentine Association of Hyperbaric Medicine and Research (AAMHEI), Buenos Aires, Argentina. The other authors, none to declare.

**References**
